"A lot of shared decision-making has to do with, what is important to the individual man?" says Dean S. Elterman, MD, MSc, FRCSC. In this interview, Dean S. Elterman, MD, MSc, FRCSC, gives an overview ...

ctDNA in metastatic RCC shows high concordance with disease progression and indolence in negative cases, indicating its prognostic value. A clinical trial is underway to explore treatment ...

"My second book is on pelvic pain or prostatitis. It is focused on a holistic approach and stretches and mindfulness exercises," says Vanita Gaglani, RPT. In this video, Vanita Gaglani, RPT, discusses ...

The Revi System showed sustained efficacy at 24 months, with 79% of patients responding to therapy and significant reductions in UUI episodes. Patient satisfaction was high, with 97% satisfied and 80% ...

Anktiva is the first drug to rescue T and NK cells, crucial for cancer cell eradication and memory generation. The "triangle offense" involves NK cells, CD8 killer T cells, and memory T cells, forming ...

Prostate cancer is the most common urologic cancer, with PSA screening reducing mortality by up to 20% in men aged 55–69. Bladder cancer incidence is stable, with early detection through urine ...

"I think this is a very important trial, just to bring some importance about patients' worries about being sexually active with urinary incontinence," says LeRoy Jones, MD. “There are a lot of social ...

Panelists explore challenges in identification of patients with intermediate-risk disease and emphasize importance of risk stratification to improve outcomes with regard to NMIBC.

“I would say both there could be an increase in MRI-guided [SBRT] and there may be increase in investigation into shrinking margins with CT-guided SBRT as well,” says Amar U. Kishan, MD. In this video ...

“Black patients have over 2-fold excess mortality compared to White men, and that has been fairly consistent; the actual rate ratio has hovered between 2 and 2.5 for many years,” says Matthew R.

Panelists discuss how FDA approvals have expanded options for BCG-unresponsive non–muscle-invasive bladder cancer (NMIBC), with pembrolizumab, nogapendekin alfa inbakicept-pmln, and nadofaragene ...